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ABSTRACT 
Proteolytic enzymes are secreted by bacteria after infection in response to host defenses or to take up 
nutrients. Enterotoxigenic Bacteroides fragilis (ETBF) is the most frequent disease-causing anaerobe in the 
intestinal tract of humans and livestock and its specific virulence factor is fragilysin, also known as B. fragilis 
toxin. This is a 21-kDa zinc-dependent metallopeptidase existing in three closely-related isoforms that hydrolyze 
E-cadherin and contribute to secretory diarrhea, and possibly to inflammatory bowel disease and colorectal 
cancer. Here we studied the function and zymogenic structure of fragilysin-3 and found that its activity is 
repressed by a ~170-residue pro-domain, which is the largest hitherto structurally characterized for a 
metallopeptidase. This pro-domain plays a role in both the latency and folding stability of the catalytic domain 
and it has no significant sequence similarity to any known protein. The pro-domain adopts a novel fold and 
inhibition of the protease domain follows an aspartate-switch mechanism. The mature catalytic fragilysin-3 
moiety is active against several protein substrates and its structure reveals a new family prototype within the 
metzincin clan of metallopeptidases. It shows high structural similarity despite negligible sequence identity to 
adamalysins/ADAMs, which have only been described in eukaryotes. Because no similar protein has been found 
outside ETBF, our findings support that fragilysins derived from a mammalian adamalysin/ADAM xenolog that 
was co-opted by B. fragilis through a rare case of horizontal gene transfer from a eukaryotic cell to a bacterial 
cell. Subsequently, this co-opted peptidase was provided with a unique chaperone and latency maintainer in the 
time course of evolution to render a robust and dedicated toxin to compromise the intestinal epithelium of 
mammalian hosts. 
 
\body 
INTRODUCTION 
The gastrointestinal tract is that part of the interface between the organism and its external environment 
where food digestion and nutrient uptake occur. The tract hosts bacteria that are beneficial for the host by 
controlling invasion and proliferation of pathogens, enhancing the immune system, processing indigestible food 
and providing essential nutrients. The most populated section of the tract is the large intestine, which is 
anaerobic and contains ten times more bacterial cells than the number of human cells in the entire body (1). 
However, in certain circumstances, this beneficial relationship can be disrupted and pathogenic bacteria can 
invade and proliferate, causing a number of disturbances. Members of the Bacteroides genus comprise the 
majority of intestinal obligate anaerobes, of which Bacteroides fragilis is most frequently associated with 
disease. Enterotoxigenic B. fragilis (ETBF) strains colonize and affect humans and livestock, and they have been 
linked to intra-abdominal abscesses, diarrhea, inflammatory bowel disease, anaerobic bacteremia, and colon 
cancer (1-3). In addition to the bacterial capsule, which induces abscess formation, the only identified virulence 
factor for ETBF is a 21-kDa zinc-dependent metallopeptidase (MP), termed B. fragilis toxin or fragilysin (4-6). It 
is synthesized as a pre-pro-protein of 397 residues, with an 18-residue signal peptide for secretion, a ~170-
residue pro-domain (PD) flanked by flexible segments, and a ~190-residue catalytic domain (CD). The latter 
encompasses two sequence elements that ascribe it to the metzincin clan of MPs: (i) an extended zinc-binding 
consensus sequence (ZBCS), HEXXHXXG/NXXH/D, which comprises three histidines that bind the catalytic 
zinc ion plus the general base/acid glutamate involved in catalysis; and (ii) a conserved methionine within a tight 
1,4- -turn, the Met-turn (5-8). However, upstream of the ZBCS there is no significant sequence similarity to any 
other metzincin, which suggests that fragilysin is a new metzincin prototype (7). 
The enzyme exists in three closely-related isoforms of identical length: fragilysin-1, -2, and -3 (alias BFT-
1, -2, and -3), which display pairwise sequence identities of 93-96% (9). Analysis of clinical isolates reveals that 
the three isoforms are generally present simultaneously (2) and that fragilysin-1 is the most abundant (see Table 
9 in (2)). The three fragilysin isoforms are encoded by a chromosomal pathogenicity islet that is absent in non-
enterotoxigenic strains. In addition to fragilysin, this island contains a second gene, mpII, which is 
countertranscribed and encodes a potential MP of similar size and moderate sequence identity (28-30%) to the 
three fragilysin isoforms. However, its potential role in ETBF pathogenesis remains to be established (2). 
The only proven substrate for fragilysin-1 in vivo is E-cadherin, an intercellular adhesion molecule. 
Shedding of E-cadherin by fragilysin-1 led to increased permeability of the epithelium and, ultimately, cell 
proliferation, which supported a role for this MP in colorectal carcinoma (10). In vitro, fragilysin-1 was shown to 
cleave type-IV collagen, gelatin, actin, fibrinogen, myosin, tropomyosin, human complement C3, and 1-
proteinase inhibitor (5, 6). The protein is stable at room temperature and below, but it undergoes rapid 
autodigestion above 37ºC. Fragilysin-3, alias BFT-3 and BFT-Korea, was shown to cleave E-cadherin in 
HT29/C1 cells similarly to isoforms 1 and 2 (9), but no further biochemical studies have been reported. 
Orally-administered broad-spectrum antibiotics may remove enteropathogens from the gastrointestinal 
tract but they also affect the beneficial and commensal flora. In the absence of this flora, opportunistic 
microorganisms may colonize the intestine and lead to severe digestion alterations and gastrointestinal diseases. 
In addition, ETBF can be resistant to antibiotics such as penicillin, ampicillin, clindamycin, tetracycline, and 
metronidazole (2). Accordingly, there is a substantiated need for understanding the origin of ETBF targets such 
as fragilysin and for the design of highly specific antimicrobials to tackle them, and detailed structural 
information greatly contributes to these aims. In order to explore the mechanisms of fragilysin activation and 
activity, we examined the proteolytic capacity of fragilysin-3 in vitro and the X-ray crystal structure of its 
zymogen, profragilysin-3, which provided a high-resolution scaffold for the design of specific inhibitors. Taken 
together with the results of phylogenetic studies, these data enabled us to propose a mechanism for latency 
maintenance and activation of this enterotoxigenic MP, as well as a plausible hypothesis for its evolutionary 
origin based on xenology (from ξένος, Greek for “stranger or “alien”), which is gene homology that is the result 
of horizontal gene transfer (HGT) between species and not of Darwinian evolution. 
 
 
 
RESULTS AND DISCUSSION 
 
Autolytic vs. heterolytic activation – Wild-type profragilysin-3 was recombinantly overexpressed in 
Escherichia coli and purified to homogeneity (Fig. S1a). Stepwise autolytic processing of profragilysin-3 via 
various intermediates was observed, which resulted in an apparently stable 21-kDa form (Fig. S1b). This protein 
started at the same residue, Ala212, as authentic fragilysin-1 purified from natural sources. In contrast, the 
Glu349Ala-mutant of profragilysin-3, which ablated the general base/acid required for catalysis, was more stable 
over time and only slight autolysis was observed (Fig. S1c). As to the possible implications of such autolysis for 
in vivo activation, previous studies on profragilysin-1 had shown that mutation of essential residues for structure 
and function eliminated proteolytic activity of the toxin but not PD processing, i.e. the latter process was exerted 
by another protease (11). Therefore, autolysis may occur in the purified recombinant proenzyme in vitro only, 
and a heterolytic activation mechanism would be responsible for activation in vivo. The most likely candidate is 
trypsin, which is widely expressed in stomach and small intestine, and also in stomach- and colon-cancer cell 
lines (12, 13). In addition, the final activation cleavage site, Arg211-Ala212, matches trypsin’s substrate 
specificity and, in our hands, limited proteolysis generated mature wild-type fragilysin-3—indistinguishable from 
the autolytically activated form—and the mature Glu349Ala-mutant, both starting at Ala212. This provided a 
means of reproducibly obtaining a homogeneous sample for subsequent studies (Fig. S1a). To assess the 
importance of the exact N-terminus of the mature peptidase, limited proteolysis experiments were further carried 
out with XXX, YYY, and ZZZ, which all cut in the flexible connecting region between PD and CD, and rendered 
different N-termini due to their disparate substrate specificities. Nonetheless, these variants evinced an activity 
that was equivalent to that of the autolytically-processed or trypsin-activated enzyme. 
Role of the pro-domain – The fragilysin-3 CD alone was difficult to express in E. coli even though a 
number of fusion constructs were assayed. It could be obtained in soluble form with an N-terminal His6-Z-tag. 
However, after fusion protein removal, the CD was observed to aggregate in size-exclusion chromatography (Fig. 
S2a). In addition, the protein did not show activity and, contrary to the mature form obtained by tryptic 
processing, it was completely digested by trypsin (Fig. S2b). Moreover, a comparative thermal shift assay was 
performed to measure the temperature of midtransition (Tm) of the two CD forms and the proenzyme. The Tm for 
trypsin-activated fragilysin-3 was ~5ºC lower than that of profragilysin-3 (Tm values of 51.4±0.9ºC and 
56.1±0.1ºC, respectively), revealing the significantly higher stability of the zyomgen due to the presence of the 
PD. In contrast, it was not possible to determine Tm for the directly expressed variant due to the anomalous 
behavior of the curve (Fig. S2c), which we attribute to a labile conformational state and aggregation. This 
hypothesis was further confirmed by circular dichroism: the spectrum of directly expressed fragilysin-3 was very 
similar to that of the trypsin-activated variant at 50ºC, i.e. under conditions of thermal denaturation of the latter 
(Fig. S2d). Taken together, all these results indicate that directly expressed fragilysin-3 is unstable and strongly 
point to a role for the PD, in addition to latency maintenance, as a chaperone that assists in the folding and 
stabilization of CD, as previously reported for other MP zymogens (14, 15). In the absence of this chaperone, 
fragilysin-3 CD is not able to fold correctly in the environment provided by the bacterial expression host. 
Proteolytic activity and its inhibition – Mature wild-type fragilysin-3 cleaved casein, fibrinogen, actin, 
and fibronectin (Fig. S1d-g), as well as a casein fluorescein-conjugate, azocollagen, and azocasein, but not 
azoalbumin in the conditions assayed. In addition, eight standard fluorogenic peptides were analyzed for 
cleavage, two of which were efficiently cleaved, including a matrix metalloproteinase (MMP) probe, NFF3 (16). 
The rest were cleaved moderately or not at all (Fig. S1i). Analysis of protein and peptide cleavage fragments 
revealed broad substrate specificity for fragilysin-3 (see Table S1), and maximal activity was recorded at pH5.5 
(Fig. S1h). As histidine side chains normally tend to be in a double protonated state at pH<~6 and this species is 
incompatible with cation binding, this maximum of activity entails that the catalytic zinc ion must be in an 
overall hydrophobic environment and very firmly bound to the protein. This is in agreement with binding 
constants exceeding 10
12
 M
-1
 reported for extracellular zinc enzymes (17). Activity was completely abolished by 
standard zinc-chelating agents and significantly impaired by excess zinc and the broad-spectrum small-molecule 
MMP inhibitor, CT1746 (18). No inhibition was exerted by inhibitors of serine, cysteine, or aspartic proteases, 
or by inhibitors of other MPs (Table S2). In contrast, only residual activity was found for the trypsin-processed 
Glu349Ala-mutant against fibrinogen and BODIPY FL-casein. Together, these results indicate that fragilysin-3 is 
an active, broad-spectrum MP in vitro. 
  Overall structure of profragilysin-3 – Profragilysin-3 is a bilobal molecule and shows the PD and the 
CD as two delimitated globular moieties (Fig. 1a). The PD is constituted by a large twisted antiparallel -sheet 
(strands 4- 8, 10, and 9), which vertically traverses the whole domain (obliquely back-to-front in Fig. 1a,b) 
and has a concave and a convex side. Preceding strand 4, an N-terminal ~40-residue segment nestles at the 
convex side of the -sheet and folds into a small three-stranded -sheet of mixed parallel ( 1 and 2) and 
antiparallel ( 3) connectivity plus an adjacent antiparallel helix, 1. The latter is inserted roughly coplanar to the 
sheet between strands 1 and 2. This sheet is orthogonal to the large -sheet and both give rise to a -sandwich 
structure (Fig. 1a,b). The strands of the large -sheet are linked by simple vertical connectivity from 4 to 8. 
Thereafter, the chain enters helix 2, which runs along the front surface, roughly top-to-bottom (Fig. 1a), and 
flows into a short 310-helix, 1, before entering the last strand of the sheet, 9, at the front of the molecule. After 
this strand, the polypeptide folds back and enters the penultimate strand of the sheet, 10, which leads to helix 
3, at the domain interface. After this helix, the chain adopts an extended conformation that includes strand 11 
and runs across the front surface of the CD (see below). The last residue defined by electron density of PD varies 
from Pro199 to Pro202 in the four independent molecules found in the crystal asymmetric unit, on the outermost 
left surface of the catalytic moiety (Fig. 1a). 
The polypeptide chain is again defined by electron density from Thr210 or Arg211, which features the 
beginning of the roughly spherical CD. This domain is divided by the active-site cleft into a large upper sub-
domain (Thr210/Arg211-Gly355) and a small lower sub-domain (Ala356-Asp397). The former consists of a 
twisted five-stranded -sheet, whose first four strands from back to front in Fig. 1a ( 13, 12, 14, and 16) run 
parallel and from left to right, whereas the outermost front strand, 15, runs antiparallel to the previous strands 
and creates the upper-rim of the active-site cleft. Loop L 14 15 protrudes from the molecular surface and 
delimitates the active-site cleft on its primed side. Two helices, the “backing helix” 4 and helix 5 are found on 
the concave and convex sides of the sheet, respectively. The upper sub-domain ends after the “active-site helix” 
6, which comprises the first part of the ZBCS and thus the first two zinc-binding histidines, His348 and His352, 
and the catalytic general base/acid, Glu349. At Gly355, still within the ZBCS, the polypeptide chain undergoes a 
sharp turn downwards and enters the lower sub-domain, which only spans 42 residues and mainly comprises the 
third zinc-binding histidine, His358; the methionine containing Met-turn (Asp364-Leu365-Met366-Tyr367); and 
the “C-terminal helix” 7, which forms part of the CD moiety (Fig. 1a). In this way, our structure confirms 
earlier hypotheses based on homology modeling of fragilysin-1 (19), which suggested that this helix formed part 
of the domain rather than protruding from it to interact with the eukaryotic membrane, as had been proposed by 
other authors (20). Interestingly, the polypeptide chain does not finish after helix 7 but adopts a loop structure 
that lies below the N-terminal segment of upper sub-domain. The chain C-terminus at Asp397 is anchored to the 
domain moiety through interactions with the side chains of His252 and Arg256 from L 4 13. It is conceivable 
that C-terminal deletion mutants disrupt this interaction network and thus impair overall stability and activity of 
the CD. This is in accordance with previous biochemical studies showing that ablation of the two C-terminal 
residues of fragilysin-1 greatly reduced activity and eight missing residues even abolished it, giving rise to an 
unstable molecule (21). 
Molecular base for zymogenicity – PDs prevent access of substrates to active-site clefts in zymogens. In 
profragilysin-3, the PD interaction with the CD exhibits good shape complementarity and covers an area of 1,996 
Å
2
 at the protein interface. The interaction involves 63 residues and comprises 98 close contacts (see Table S4). 
In contrast to metalloprocarboxypeptidases of the funnelin tribe of MPs (22) and to pro-MMPs (23), the PD does 
not cap the CD but is attached to its right lateral surface (Fig. 1a). It prevents access to the active-site cleft 
through the C-terminal segment, which runs in extended conformation across the entire CD front in the opposite 
orientation to a substrate. The most important segment for latency is that encompassing 3, L 3 11 and 11, 
which traverses the front of the CD from right to left. It establishes a parallel -sheet interaction on the non-
primed side of the cleft through strand 11 with “upper-rim strand” 15 of the CD (Fig. 2a,b and Table S4). It 
also approaches the beginning of helix 5 above the cleft, as well as L 14 15, L 15 16, L 16 6, active-site 
helix 6, and the segment connecting the Met-turn with C-terminal helix 7. Additional segments involved in 
PD/CD interaction include the solvent-accessible part of the backing helix 4 of the CD and the concave side of 
the large PD -sheet, which contributes with residues from 5- 8 and 10; a parallel -sheet consisting of 
strands 13 (CD) and 4 (PD); and segments 3 and L 3 11 (PD) and helix 5 and loops L 15 16, L 6 7, 
and L 16 4 (CD). A prominent bulge preceding 11 gives rise to a tight 1,4-turn spanning Tyr191-Asp194 (Fig. 
2a,b). This bulge causes the side chains of Tyr191 and Asp194 to penetrate the catalytic moiety while the 
residues embraced, Ile192 and Asn193, point to the bulk solvent. The aromatic residue occupies the S1’ site of 
the cleft, which is framed by atoms provided by Ile313, Leu314, Gly344, Val345, His352, His358, Leu365, and 
Tyr370, as well as by backbone atoms of segment Leu365-Leu374 (Fig. 2b).  This is a large pocket (360 Å
3
) and 
Tyr191 is a long way from filling it. Although most of the framing side chains are hydrophobic, the pocket could 
also accommodate short side chains and large hydrophilic residues, which could be bound by the main-chain 
carbonyl groups of Leu365, Asp364, Tyr367, or Tyr373, or by Thr371 O 1. Accordingly, this pocket would be 
compatible with a broad specificity. Asp194, in turn, co-ordinates the catalytic zinc ion in substitution of the 
solvent molecule usually found in mature CDs primed for catalysis (24). The binding is bidentate and exerted 
from the top by the two terminal carboxylate oxygen atoms, which together with the N 2 atoms of His348, 
His352, and His358 give rise to a tetrahedral+1 co-ordination sphere of the catalytic zinc (Fig. 1c). This 
inhibitory mechanism follows an “aspartate switch”, in analogy to MMPs and ADAMs/adamalysins, for which 
the term “cysteine switch” was coined. The name was based on a cysteine S  atom replacing the catalytic solvent 
molecule in the zymogen (25, 26). In addition, Asp194 O 2 points to the O 1 atom of the general base/acid, 
Glu349, at 2.69-3.04Å in the four monomers in the asymmetric unit (Fig. 2b). This implies that one of the 
oxygens must be protonated. Downstream of Asp194, Tyr195 most likely occupies cleft sub-site S2, framed by 
His352, Leu319, and His358; and Ile196 is probably in S3, shaped by Trp318, Leu280, As277, and Ile316 (Fig. 
2a,b). As observed for S1’, these sites could harbor several types of residue, thus supporting the broad substrate 
specificity of fragilysin-3 observed in vitro. 
Structural similarities – We found no overall similarity between the PD and any other structure 
deposited with the Protein Data Bank (PDB). Only the functionally unrelated bacteriochlorophyll A binding 
protein from the green sulfur bacterium, Prosthecochloris aestuarii 2K, showed similarity with the central part of 
the large -sheet and helix 2 (PDB 3EOJ; (27); Z-score 4.3, rmsd 5.3Å, 106 common residues; 6% sequence 
identity) (Fig. S3a). However, in the Prosthecochloris protein, the -strands are much longer and form part of an 
overall open-barrel structure with no resemblance to profragilysin-3. In addition, topological relatedness includes 
only about 50% of PD residues: the small orthogonal -sheet and helix 1, on the convex side of the large sheet, 
as well as helices 1 and 3 of PD, do not have structural equivalents in the Prosthecochloris protein. 
Accordingly, we conclude that profragilysin-3 PD conforms to a new fold, understood as a domain with a 
structure formed by regular secondary structure elements in an orientation and connectivity not found in 
previously reported molecules.  
In contrast, searches with the CD unambiguously identified members of the adamalysin/ADAMs family 
as close structural relatives of fragilysin-3, with Z-scores of 13-17, rmsd values of 2.5-2.9Å, and common 
sequence stretches of 160-166 residues (out of 188 total residues in fragilysin-3 and 200-260 in 
adamalysin/ADAM catalytic moieties) but only ~15% sequence identity. Next in similarity was ulilysin, the 
structural prototype of the pappalysin family, followed by MMPs, serralysins, and astacins, which are all 
members of the metzincin clan of MPs (7, 8). Fig. S3b depicts the superposition of fragilysin-3 with adamalysin 
II (PDB 1IAG; (28, 29)), which reveals that almost all their regular secondary structure elements colocalize. Both 
CDs display a large upper sub-domain of ¾ and a small lower sub-domain of ¼ of the total size. With helix 5, 
fragilysin-3 has one of the most characteristic elements for adamalysins/ADAMs not present in any other 
metzincin prototype, the large “adamalysin helix” preceding the central strand of the upper sub-domain -sheet 
(7). Furthermore, the upper-rim strand and the preceding bulge on top of the cleft on its primed side are very 
similar in both structures, both in length and conformation.  
The adamalysin/ADAM family is named after the first family member to be structurally characterized, 
adamalysin II from Crotalus adamanteus snake venom, and mammalian reproductive-tract proteins (30, 31). The 
family has 40 members in humans (http://degradome.uniovi.es/met.html#M10) and has only been found in 
metazoans and some fungi, which include two opportunistic human pathogens, Pneumocystis carinii and 
Aspergillus fumigatus; and fission yeast, Schizosaccharomyces pombe (7, 32-34). Sequence similarity searches 
within bacteria and archaea revealed potential adamalysin-like sequences only in Marinobacter aquaeolei and 
Marinobacter algicola, which, however, have yet to be characterized. Since fragilysins showed only 15% 
sequence identity with adamalysins/ADAMs, we performed a phylogenetic analysis including four human, two 
ophidian, and two fungal adamalysins/ADAMs, in addition to the putative Marinobacter relatives and fragilysin-
3 (Fig. S3c). This study revealed that the metazoan forms cluster together. Next in divergence would be the two 
Marinobacter relatives, followed by the fungal forms. Fragilysin-3 would be clearly farthest away in evolution, 
indicating that fragilysins are not true adamalysins/ADAMs anymore despite the close overall structure due to 
the action of evolution in a particular environment. Consistent with this separation, there are several subtle 
differences between fragilysin-3 and adamalysin II (Fig. S3b).  
Implications for fragilysin isoforms – The sequence identity values indicate that the three profragilysin 
isoforms have identical structure. They all span 397 residues, and differences in sequence of profragilysin-3 
(UniProt O86049) with profragilysin-1 (Q9S5W0) and -2 (O05091) are found at just five positions in PD and at 
26 positions in CD (Table S5). Interestingly, almost half of the mutations (12/26) cluster at the lower sub-domain 
of the CD. All changes are compatible with the current structure as they mostly affect surface-exposed segments. 
Only three mutants, Asp277Lys, Asn312Lys, and Lys331Glu, only present in fragilysin-1, could affect substrate 
binding and alter distant sub-sites at both ends of the cleft, i.e. beyond S5 and S3’. In any case, no mutation 
affects the residues shaping pockets S1 and S1’, which were reported to preferentially accommodate hydrophobic 
residues in the case of fragilysin-1 (5, 6). As fragilysin-3 shows broad specificity (Table S1), we do not have a 
structural explanation for these differences. Overall, the conclusions of this structural analysis can be 
extrapolated to all three isoforms, which is consistent with a common function in vivo. 
Conclusions – Until the discovery of fragilysins, the main molecular determinants of ETBF virulence, no 
MP had been reported to act as a potent enterotoxin (19). We showed here that fragilysin-3 is a functional broad-
spectrum MP in vitro with a large S1’ pocket that could be targeted by specific inhibitors to treat ETBF infection 
and associated diseases. In vivo, this MP is inhibited by a novel PD via an aspartate-switch mechanism until it is 
secreted to the gut lumen. Fragilysin-3 is one of three isoforms present in ETBF and no further related proteins 
have been described. They are encoded by a pathogenicity islet, which is absent in non-virulent B. fragilis 
strains, that must have been acquired by HGT from an exogenous source (35). HGT may occur through nucleic-
acid transduction, conjugation, or transformation, and it contributes to evolution of life complementing the 
Darwinistic tree-based mechanism. It results in the acquisition of xenologs, i.e. homologs that do not result from 
common ancestor inheritance, and confers adaptive advantages that can change the relationship of bacterial 
species with the environment and their pathogenic character (36). Such gene shuffling is common within and 
across bacteria and archaea and examples include the transfer of resistance plasmids (37). Contrary, documented 
transfer from bacteria to eukaryotic cells is restricted to few examples, among them the interaction between 
Agrobacterium tumefaciens and plant cells, which leads to Crown-Gall disease (38, 39). Lastly, gene transfer 
from eukaryotes to bacteria is extremely uncommon and only detectable through phylogenetic and comparative 
genome analyses (40, 41). It is of great potential relevance for bacterial pathogenicity (36, 40). Direct evidence 
for such HGT does not exist as there is no footprint of such evolutionary processes and, therefore, sequence-
independent structural similarity provides a complementary tool to unveil potential cases of xenolog exaptation. 
In this sense, the CD structure, but not the sequence, of fragilysin-3 strongly resembles adamalysins/ADAMs 
only and it is conceivable that fragilysins derived from a xenolog of adamalysins/ADAMs co-opted long ago 
during the intimate coexistence between B. fragilis and mammalian intestinal tracts. Fragilysins would 
subsequently have evolved in a bacterial environment, thus giving rise to small structural changes and a different 
protein sequence expressed as three isoforms, and, putatively, to the gene product of mpII. In this context, it has 
been shown that human colon cell lines express mRNA of ADAM-10, -12, and -15 (42), which could potentially 
be incorporated by competent intestinal bacteria by transformation and subsequent action of DNA polymerase I, 
which exerts RNA-dependent DNA polymerase activity in several bacteria (43). In addition, mammalian 
adamalysin/ADAM CDs are difficult to produce as recombinant proteins and they require PDs that work as 
intramolecular chaperones (44). The same is the case for fragilysin-3, which could only be produced in a 
functional form if fused to its unique and tailor-made PD. All these lines of evidence support a relation between 
the aforementioned mammalian MPs and fragilysins and, thus, the development of a functional protein, which 
eventually became toxic for the intestinal wall: putatively the origin of its own ancestor. 
 
MATERIALS AND METHODS 
 
A detailed description of procedures is provided in SI Materials and methods. Briefly, profragilysin-3 was 
amplified from genomic B. fragilis DNA and cloned into a modified pET-28a vector for overexpression in E. coli 
Origami-2 (DE3) cells. The protein was purified by nickel-affinity chromatography, digested with tobacco-etch 
virus protease to remove the N-terminal hexahistidine tag, and polished by gel filtration. The selenomethionine 
variant was obtained in the same way, except that cells were grown in minimal medium implemented with amino 
acids, with selenomethionine replacing methionine. The Glu349Ala mutant was obtained by site-directed 
mutagenesis and produced as aforementioned. The active wild-type enzyme was obtained by time-dependent 
autolysis or tryptic limited proteolysis of the zymogen and subsequent gel-filtration purification. Thermal shift 
and circular dichroism assays, as well as proteolytic activity assays against protein and peptide substrates and 
inhibitory assays, were performed according to standard protocols. The crystal structure of profragilysin-3 was 
solved by single-wavelength anomalous diffraction by using orthorhombic selenomethionine-derivatized crystals 
obtained by sitting-drop vapor diffusion. Program SHELXD was used to identify all 20 selenium sites of the 
dimer present in the asymmetric unit and the non-crystallographic symmetry operator could be derived. 
Subsequent phasing with SHELXE and density modification with DM under twofold averaging rendered an 
electron density map that enabled manual tracing of roughly ¾ of each protomer. These coordinates were refined 
with REFMAC5 and used to solve the structure of monoclinic native crystals, which contained a tetramer per 
asymmetric unit, by Patterson search with PHASER. A subsequent run with ARP/wARP rendered an excellent 
electron density map. Thereafter, manual model building alternated with crystallographic refinement until the 
model was complete. Phylogenetic analyses were performed with MULTALIN and PHYLIP after optimal 
superposition of the available crystal structures to derive a sequence alignment. 
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FIGURE LEGENDS  
Figure 1. Overall structure of profragilysin-3. (A) Richardson-type plot of profragilysin-3 in stereo with 
helices (labeled 1- 7 and 1) as ribbons and -strands ( 1- 15) as arrows. The polypeptide chain is flexible 
and thus interrupted between the end of the PD (depicted in magenta) and the beginning of the CD (cyan). The 
latter is displayed approximately in the standard orientation characteristic for MPs, i.e. with the view into the 
active-site cleft, which runs from left (non-primed side) to right (primed side) according to (45). (B) Topology of 
profragilysin-3 PD displaying the regular secondary structure elements, which comprise strands 1- 11 (arrows) 
and helices 1- 3 plus 1 (rods). Strands 4 and 11 establish parallel -sheet interactions with CD strands 13 
and 15 (in cyan), respectively. (D) Zinc-binding site of profragilysin-3 with the metal ion in magenta and the 
coordinating residues from the PD (Asp349) and the CD (His348, His352, and His358). The distance ranges for 
each bond found in the four molecules of the asymmetric unit of the wild-type structure are depicted.  
Figure 2. Active-site cleft of profragilysin-3. (A) Detail of the active-site cleft of fragilysin-3 
superimposed with its Connolly surface colored according to electrostatic potential. PD segment Cys189-Thr198 
is shown as a stick model. (B) Close-up view of Fig. 1a in stereo showing the active-site environment, the 
specificity pocket, and the residues involved. All residues except those already tagged in Fig. 1c are labeled. 
